GlassScriptPhysician profile
Scott Andrew Corman
NPI 1750584991
$13,603.07
in general payments reported to CMS, 2019-2025
41 companies · $2,891 in 2025
The $2,891 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,592 · 2020: $1,348 · 2021: $1,601 · 2022: $1,967 · 2023: $2,067 · 2024: $2,137 · 2025: $2,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,076 · Education: $19.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,075.63 |
| Education | $19.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,332.47 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $3,026.90 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,222.85 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $940.12 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $696.62 | 2019-2025 | |
| Pfizer INC. | $507.77 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $381.82 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $336.72 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $324.69 | 2022-2025 | Dupixent |
| Celgene Corporation | $323.60 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $271.52 | 2023-2025 | Zenpep, Vowst |
| Intercept Pharmaceuticals, INC. | $237.37 | 2020-2025 | Ocaliva |
| Qol Medical, LLC | $236.51 | 2020-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $211.05 | 2019-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $147.20 | 2020-2023 | Dificid, Zinplava |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $130.41 | 2024-2025 | Omvoh |
| Medtronic, INC. | $126.96 | 2022 | |
| Ucb, INC. | $112.73 | 2019-2020 | |
| Ardelyx, INC. | $105.84 | 2022-2024 | Ibsrela |
| Romark Laboratories, Lc | $96.47 | 2019-2020 | |
| Shionogi INC | $96.28 | 2019 | |
| Celltrion USA INC. | $93.67 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Braintree Laboratories, INC. | $92.98 | 2019-2023 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $89.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $73.11 | 2019-2023 | Injectafer |
| Endo Pharmaceuticals INC. | $41.78 | 2019 | |
| Enterra Medical, INC. | $38.45 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.05 | 2023 | Cyltezo |
| Shire North American Group INC | $34.01 | 2019 | |
| Capsovision, INC. | $29.97 | 2024 | Capsocam Plus |
| Organon LLC | $24.29 | 2023 | Renflexis, Hadlima |
| Redhill Biopharma INC. | $24.09 | 2021 | |
| Mylan Institutional INC. | $22.22 | 2023 | Hulio |
| Novo Nordisk INC | $21.72 | 2025 | Wegovy |
| Lucid Diagnostics INC. | $20.83 | 2024 | |
| Ironwood Pharmaceuticals, INC | $18.75 | 2024 | |
| Amgen INC. | $18.75 | 2023 | Amjevita, Avsola |
| Evoke Pharma, INC. | $17.62 | 2021 | |
| Alfasigma USA, INC. | $13.97 | 2020 | |
| Fresenius Kabi USA, LLC | $13.71 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $13.16 | 2024 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Corman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.